Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report details a specific share repurchase transaction executed on September 26, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 55,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,305 pence per share; lowest price paid was 1,299 pence per share.
- Treasury Shares Held: 505,396,816 shares (representing 9.07% of total issued share capital and 9.98% of total voting rights).
- Shares in Issue: 5,065,608,945 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's issued share capital through the cancellation of 55,000 repurchased shares. This transaction slightly adjusted the total number of shares held in Treasury and the outstanding share count used for voting rights calculations.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,065,608,945) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (505,396,816) and its percentage of total voting rights (9.98%).
- Note that this filing does not contain operational or financial performance data for the period.